Novartis (NOVN.SW) Stock Price
Novartis Price
Novartis (NOVN.SW) Stock | ISIN CH0012005267 | WKN 904278. The current Novartis stock price is 149.8 USD (2026). Revenue is 58.17 B USD. Net income is 18.23 B USD. The P/E ratio is 16.06. Market capitalization is 292.85 B USD. Novartis operates in the Health sector.
Revenue has compounded at 2.5% per year over the past 19 years to 56.33 B USD. Earnings per share have grown at 4.6% per year over the last 19 years. Novartis's net margin stands at 24.8%, down from 54.6% several years earlier. Novartis currently offers a dividend yield of about 2.34%. The payout ratio is around 65% of earnings. The dividend has grown at 6% per year over the past 19 years.
Novartis stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Novartis over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Novartis stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Novartis's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Novartis Price |
|---|
Novartis Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Novartis Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (B USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (B USD) |
| NET INCOME (B USD) |
| NET INCOME GROWTH (%) |
| DIVIDEND (USD)DIV. (USD) |
| DIVIDEND GROWTH (%)DIV. GROWTH (%) |
| SHARES (B) |
| DOCUMENTS |
| 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|
| 51.72 | 56.33 | 58.17 | 60.94 | 64.31 | 66.85 | 70.26 | 69.76 |
| 10.85 | 8.91 | 3.27 | 4.76 | 5.53 | 3.95 | 5.1 | -0.71 |
| 75.22 | 75.82 | 73.42 | 70.08 | 66.41 | 63.89 | 60.79 | 61.22 |
| 38.91 | 42.71 | 42.71 | 42.71 | 42.71 | 42.71 | 42.71 | 42.71 |
| 11.94 | 13.98 | 18.23 | 19.55 | 21.84 | 22.63 | 23.81 | 23.82 |
| -19.59 | 17.11 | 30.39 | 7.23 | 11.68 | 3.63 | 5.22 | 0.04 |
| 3.3 | 3.5 | 3.7 | 5.96 | 6.84 | - | - | - |
| 3.12 | 6.06 | 5.71 | 61.08 | 14.77 | – | – | – |
| 2.04 | 1.96 | 1.96 | 1.96 | 1.96 | 1.96 | 1.96 | 1.96 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Novartis generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Novartis retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Novartis's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Novartis has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Novartis's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Novartis stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Novartis Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Novartis business model & stock analysis
Novartis SWOT Analysis
Strengths
[ { "heading": "1.", "text": "Strong" }, { "heading": "2.", "text": "Diverse" }, { "heading": "3.", "text": "Solid" } ]
Weaknesses
[ { "heading": "1.", "text": "Dependence" }, { "heading": "2.", "text": "Product" }, { "heading": "3.", "text": "Limited" } ]
Opportunities
[ { "heading": "1.", "text": "Growing" }, { "heading": "2.", "text": "Expansion" }, { "heading": "3.", "text": "Acquisitions" } ]
Threats
[ { "heading": "1.", "text": "Intense" }, { "heading": "2.", "text": "Stringent" }, { "heading": "3.", "text": "Potential" } ]
Novartis Eulerpool Fair Value
Novartis historical P/E ratio, EBIT multiple, and P/S ratio
Novartis annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Novartis shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Novartis Dividend History
30 years of dividend payments · 23 consecutive increases
Novartis dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Novartis dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Novartis Earnings Estimates
Novartis Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 10/25/2022 | 1.58USD | 13.04 BUSD | 2022 Q3 |
| 7/19/2022 | 1.53USD | 13.04 BUSD | 2022 Q2 |
| 4/26/2022 | 1.47USD | 12.88 BUSD | 2022 Q1 |
| 2/2/2022 | 1.45USD | 13.55 BUSD | 2021 Q4 |
| 10/26/2021 | 1.68USD | 13.22 BUSD | 2021 Q3 |
| 7/21/2021 | 1.57USD | 12.71 BUSD | 2021 Q2 |
| 4/27/2021 | 1.59USD | 12.71 BUSD | 2021 Q1 |
| 1/26/2021 | 1.4USD | 13.08 BUSD | 2020 Q4 |
| 10/27/2020 | 1.48USD | 12.76 BUSD | 2020 Q3 |
| 7/21/2020 | 1.35USD | 12.07 BUSD | 2020 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Novartis stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Novartis shareholder structure
| % | Name |
|---|---|
7.13003% | |
5.93294% | |
3.31466% | |
2.57639% | |
1.46729% | |
1.44436% | |
0.89051% | |
0.8308% | |
0.70931% | |
0.70925% |
Novartis Executives and Management Board
Dr. Vasant Narasimhan
(49)Chief Executive Officer, Member of the Executive Committee
Mr. Harry Kirsch
(60)Chief Financial Officer, Member of the Executive Committee
Mr. Aaron Gal
(59)Chief Strategy and Growth Officer, Member of the Executive Committee
Dr. Fiona Marshall
(61)President - Biomedical Research, Member of the Executive Committee
Dr. Steffen Lang
(58)President - Operations, Member of the Executive Committee
Novartis Supply Chain
Frequently asked questions about Novartis
The business model of Novartis AG focuses on the development, manufacturing, and commercialization of innovative healthcare solutions. As one of the leading pharmaceutical companies globally, Novartis AG operates in three main segments: Pharmaceuticals, which includes patented prescription medicines; Alcon, which deals with eye care products; and Sandoz, responsible for generic pharmaceuticals and biosimilars. Novartis AG strives to improve patient outcomes by investing heavily in research and development, collaborating with healthcare professionals, and implementing cutting-edge technologies. By combining scientific expertise with a patient-centric approach, Novartis AG aims to address unmet medical needs and contribute to the advancement of healthcare worldwide.
Novartis stock
Novartis Peer Group
Novartis Ticker
Novartis FIGI
All fundamentals and in-depth analysis of Novartis
Our stock analysis for Novartis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novartis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.